Aemetis Inc. (NASDAQ: AMTX) saw its share price climb 4.3% on Tuesday following an announcement that its India affiliate, Universal Biofuels, had locked in supply contracts valued at about $17 million.
The agreements call for Universal Biofuels to deliver in excess of 18 million liters of biodiesel to three government-owned Oil Marketing Companies (OMCs) over a three-month period. The deliveries are intended to support India’s National Policy on Biofuels, which currently targets an increase in biodiesel blending from the present level of 1% to 5% by 2030.
In addition to meeting OMC obligations, Universal Biofuels is providing distilled biodiesel to private commercial customers. Company statements indicate that additional fuel supply orders from OMCs are expected to materialize before the end of 2026.
Universal Biofuels operates one of the larger biodiesel production sites in India, located in Kakinada. The facility has an annual capacity of approximately 80 million gallons and has been in operation for more than 18 years. The plant uses a proprietary enzymatic process intended to yield biodiesel with lower carbon intensity.
Management has signaled interest in broadening the subsidiary’s footprint across India. Expansion plans under consideration include new production locations and diversification into adjacent sustainable energy products such as dairy biogas, ethanol, and sustainable aviation fuel.
Universal Biofuels is also preparing for a potential initial public offering on an Indian stock exchange to sell a minority equity stake to public investors, with any offering dependent on prevailing market conditions.
Below are the primary takeaways and considerations derived from the company announcement and operational disclosures.
- Market movement: Aemetis shares rose 4.3% following the contract announcement.
- Contract scope: The agreements represent roughly $17 million in biodiesel sales and more than 18 million liters to three government-owned OMCs over three months.
- Facility scale: The Kakinada plant has roughly an 80 million gallon per year capacity and has operated for over 18 years using a proprietary enzymatic production method.
The information provided in company releases frames near-term revenue recognition from the scheduled deliveries, signals potential follow-on OMC orders before the end of 2026, and outlines strategic options the subsidiary is exploring, including diversification and an India IPO subject to market conditions.